Northwest Biotherapeutics Inc. has begun construction on its first Grade C manufacturing suite at its Sawston, UK facility, signaling a significant expansion of its production capabilities. The new suite, expected to more than double the current aggregate capacity of existing Grade B suites, represents a major step toward large-scale manufacturing of the company's DCVax® personalized immune therapies for solid tumor cancers. Construction is projected to take approximately six months, with manufacturing in the new suite anticipated to begin in the second quarter of next year. The upgrade leverages the Flaskworks closed system, enabling the transition from Grade B to Grade C suites and supporting the company's plans for large-scale operations.